After moving -1.7% during today's evening session, Moderna is now trading at a price of $105.8 per share. On average, analysts give it a target price of $181.47.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Moderna Investors Should Consider This:
-
Moderna has moved -25.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 0.51. A number between 0 and 1 could mean that the market is undervaluing Moderna's estimated growth potential
-
Its Price to Book (P/B) ratio is 2.38
Understanding Moderna's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-24 | 19,263,000 | -4,427,000 | 49 | -31.94 |
| 2022-02-25 | 18,471,000 | -2,558,000 | 72 | 175.79 |
| 2021-02-26 | 803,000 | -1,558,000 | -95 | 89.56 |
| 2020-02-27 | 60,000 | -606,000 | -910 | -197.39 |
| 2019-02-06 | 135,068 | -548,334 | -306 |
Averaging out to -238.0% over the last 5 years, Moderna's operating margins also have a high coefficient of variability, which stands at 170.0%. The firm's margins exhibit a relatively stable growth trend of 3.0%.
